The 2026 EMA–FDA Guiding Principles of Good AI Practice

The 2026 EMA–FDA Guiding Principles of Good AI Practice In this episode of Center of Excellence - Pharma 4.0, we unpack the landmark 2026 joint guidance from the U.S. Food and Drug Administration and the European Medicines Agency—the Guiding Principles of Good AI Practice (GAIP). As artificial intelligence rapidly transforms drug discovery, clinical development, manufacturing, and pharmacovigilance, regulators are setting clear expectations for how AI must be designed, validated, and governed across the pharmaceutical lifecycle. This episode decodes the ten GAIP principles and explains why they represent a turning point: shifting AI from experimental innovation to a regulated, compliance-driven asset. We explore how human-centric design, risk-based validation, robust data governance, and lifecycle management are becoming non-negotiable requirements. The discussion also connects GAIP with the broader regulatory landscape—including the EU AI Act and evolving GMP frameworks—highlighting how these converging regulations will reshape Pharma 4.0 strategies. Listeners will gain practical insights into the immediate actions organizations must take: building AI inventories, establishing multidisciplinary governance models, strengthening data traceability, and preparing for continuous model monitoring. Whether you're in regulatory affairs, quality, digital transformation, or AI development, this episode provides a clear roadmap to navigate the fast-approaching compliance horizon and build regulatory trust in an AI-driven future. Resources: Book Series: Center of Excellence – Pharma 4.0 https://www.amazon.com/dp/B0F1DX4XXB Udemy Course: Smart Manufacturing in Pharma https://www.udemy.com/course/smart-manufacturing-in-pharma/ Subscribe to our YouTube channel https://www.youtube.com/@COE-PHARMA4.0 Website: https://respa.com and follow the Podcast https://pharma4coe.podbean.com for more insights on the future of Pharma! #Pharma40 #ArtificialIntelligence #AIinPharma #RegulatoryCompliance #FDA #EMA #GAIP #EUAIAct #DigitalTransformation #PharmaInnovation #GxP #SmartManufacturing #LifeSciences #AICompliance #HealthcareInnovation